While modern cephalosporins developed for broad spectrum antibacterial activities have never been pursued for tuberculosis (TB) therapy, we identified first generation cephalosporins having clinically relevant inhibitory concentrations, both alone and in synergistic drug combinations. Common chemical patterns required for activity against Mycobacterium tuberculosis were identified using structure-activity relationships (SAR) studies. Numerous cephalosporins were synergistic with rifampicin, the cornerstone drug for TB therapy, and ethambutol, a first-line anti-TB drug.
Original Source [2]
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/repurposing-clinically-approved-cephalosporins-tuberculosis-therapy
[2] http://www.nature.com/articles/srep34293
[3] http://admin.indiaenvironmentportal.org.in/category/author/santiago-ram%C3%B3n-garc%C3%ADa
[4] http://admin.indiaenvironmentportal.org.in/category/author/rub%C3%A9n-gonz%C3%A1lez-del-r%C3%ADo
[5] http://admin.indiaenvironmentportal.org.in/category/author/angel-santos-villarejo-et-al
[6] http://admin.indiaenvironmentportal.org.in/category/journal/scientific-reports
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/tuberculosis
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/antibiotic
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
